ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03482050
Recruitment Status : Recruiting
First Posted : March 29, 2018
Last Update Posted : August 8, 2018
Sponsor:
Information provided by (Responsible Party):
Kadimastem

Brief Summary:

This is a study of transplantation of Astrocytes derived from human embryonic stem cells, in patients with Amyotrophic Lateral Sclerosis (ALS).

There will be no change in the routine ALS treatment of the patients enrolled into the study. Treatment will be administered in addition to the appropriate standard of care treatment.

The study hypothesis is that transplantation of Astrocyte(AstroRx) cells can compensate for the malfunctioning of patients' own astrocytes by restoring physiological capabilities like the reuptake of excessive glutamate, reducing oxidative stress, reducing other toxic compounds, as well as by secreting different neuroprotective factors


Condition or disease Intervention/treatment Phase
ALS (Amyotrophic Lateral Sclerosis) Biological: AstroRx Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Intervention Model: Sequential Assignment
Intervention Model Description: Dose-escalating, four subject-groups clinical study; a single treatment administration of AstroRx, administered in an escalating low, medium and high dose or two consecutive administrations of the medium dose separated by an interval. AstroRx will be administered by intrathecal (spinal) injection to subjects with ALS at the early disease stage.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Theraputic Effects of Transplantation of Astrocytes Derived From Human Embryonic Stem Cells (hESC), in Patients With Amyotrophic Lateral Sclerosis (ALS)
Actual Study Start Date : April 12, 2018
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020


Arm Intervention/treatment
Experimental: AstroRx Biological: AstroRx
Astrocytes derived from human embryonic stem cells




Primary Outcome Measures :
  1. Number of participants with treatment emergent adverse events as assessed by CTCAE Version 4.03 [ Time Frame: 11 Months ]
    Safety and tolerability assessment will be based on treatment emerged adverse events


Secondary Outcome Measures :
  1. Change in the ALS functional rating scale [ Time Frame: 11 Months ]
    Preliminary efficacy assessment to measure response to treatment or progression of disease. Scale includes 12 questions related to tasks. Each task rated on a five-point scale from 0 = unable to do the task, to 4 = normal ability. Individual item scores are summed to produce a reported score of between 0 = worst and 48 = best.

  2. Change in predicted slow vital capacity (%SVC) [ Time Frame: 11 Months ]
    Preliminary efficacy assessment to measure respiratory muscle strength

  3. Change in muscle strength grading by JAMAR grip strength [ Time Frame: 11 Months ]
    Preliminary efficacy assessment to measure hand grip strength

  4. Change in muscle strength grading by hand held dynamometer (HHD) [ Time Frame: 11 Months ]
    Preliminary efficacy assessment to measure muscle strength in limb muscles

  5. Change in Quality of Life questionnaire (ALSAQ-40) [ Time Frame: 11 Months ]
    Preliminary efficacy assessment to measure the subjective well-being of patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. El Escorial criteria for probable or definite ALS
  2. Males and and non pregnant females between 18 and 70 years of age
  3. Patients with an ALS-FRS-R score of at least 30 with an ALS diagnosis of two years or less
  4. No history of active psychiatric disorder.
  5. Patient has a good understanding of the study and nature of the procedure
  6. Patient provides written informed consent prior to any study procedure
  7. Patients should either be on a stable dose of Riluzole and/or Radicava® (if applicable) for 3 months, or not be treated with Riluzole or Radicava®
  8. Patient is medically able to tolerate immunosuppression regimen
  9. Presence of a willing and able caregiver who understands the need to attend all follow-up visits, even if mobility declines

Main Exclusion Criteria:

  1. Patient has a past infection or a positive test for HBV,HCV or HIV
  2. Patient is in need of respiratory support
  3. Patient has a lower than 10/12 in ALS-FRS-R respiratory parameters or below 70% of predicted slow vital capacity (SVC)
  4. Patient has renal failure
  5. Patient has impaired hepatic function
  6. Patient has a Body Mass Index (BMI) of <18.5 or > 30
  7. Patient suffers from significant cardiac disease, diabetes, autoimmune diseases, chronic severe infection, malignant disease or any other disease or condition that may risk the patient or interfere with the ability to interpret the study results
  8. Patient has systemic inflammation or active infections
  9. Patient has been treated previously with any stem cell therapy
  10. Current use of immunosuppressant medication or use of such medication within 6 weeks of Screening visit (Visit 0)
  11. Patient has participated in another clinical treatment trial or received other experimental medications outside of a clinical trial within 1 month prior to start of this study
  12. Any known immunodeficiency syndrome
  13. Any concomitant disease or condition limiting patient safety to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03482050


Contacts
Contact: Yael Feinsod +972-2-6779372 HCRC_ALS@hadassah.org.il

Locations
Israel
Hadassah Ein Kerem Medical Center Recruiting
Jerusalem, Israel
Contact: Yael Feinsod         
Principal Investigator: Marc Gotkine, MD         
Sponsors and Collaborators
Kadimastem

Responsible Party: Kadimastem
ClinicalTrials.gov Identifier: NCT03482050     History of Changes
Other Study ID Numbers: ASTRO-001-IL
First Posted: March 29, 2018    Key Record Dates
Last Update Posted: August 8, 2018
Last Verified: April 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases